Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $97 to $87.